Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Gross Margin (2017 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Gross Margin for 9 consecutive years, with 93.64% as the latest value for Q1 2026.

  • For Q1 2026, Gross Margin rose 608.0% year-over-year to 93.64%; the TTM value through Mar 2026 reached 90.04%, up 252.0%, while the annual FY2025 figure was 88.26%, 33.0% down from the prior year.
  • Gross Margin hit 93.64% in Q1 2026 for Agios Pharmaceuticals, up from 90.59% in the prior quarter.
  • Across five years, Gross Margin topped out at 93.64% in Q1 2026 and bottomed at 59.25% in Q1 2022.
  • Average Gross Margin over 5 years is 87.27%, with a median of 90.12% recorded in 2023.
  • On a YoY basis, Gross Margin climbed as much as 3087bps in 2023 and fell as far as -871bps in 2023.
  • Agios Pharmaceuticals' Gross Margin stood at 90.42% in 2022, then rose by 1bps to 91.75% in 2023, then decreased by -4bps to 88.26% in 2024, then rose by 3bps to 90.59% in 2025, then rose by 3bps to 93.64% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 93.64%, 90.59%, and 86.96% for Q1 2026, Q4 2025, and Q3 2025 respectively.